E2F3-IT1 and retinoblastoma: In this context, He et al., in 2020 demonstrated in a promising study that GapmeR-mediated lncRNA retinoblastoma associated transcript-1 (RBAT1) silencing inhibited tumorigenesis in RB, and given that GapmeR antisense oligonucleotides can freely cross the blood-eye barrier, antisense drugs targeting this lncRNA may be an interesting therapeutic option for RB patients (He et al., 2020).